Investment Banking
Exclusive Financial Advisor to VirtuOx on its Sale to Resmed
May 27, 2025
Oppenheimer & Co. Inc. acted as exclusive financial advisor to VirtuOx, a founder-owned software-enabled independent diagnostic testing facility and provider of technology solutions to facilitate in-home and remote testing services for sleep, respiratory, cardiac, and other health conditions across the United States.
Resmed Inc. (NYSE: RMD) is a leading health technology company focused on sleep, breathing, and care delivered in the home.
The acquisition reflects Resmed’s commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx’s at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected way.VirtuOx’s virtual testing platform helps reduce barriers to diagnosis, offering fast, flexible, and affordable options for patients—particularly those with sleep-disordered breathing or other conditions that are often underdiagnosed.
This transaction is one of three healthcare M&A transactions that Oppenheimer has advised on in the last month.
Name:
Don Ritucci
Title:Managing Director, Head of Healthcare Mergers & Acquisitions
Name:
Will Hart
Title:Executive Director
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2025 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 7992555.1